Teva shares hit fresh 52-week high after FDA approves monthly shot
NYSE-listed Teva Pharmaceutical Industries (TEVA) rallied to fresh 52-week highs after the U.S. FDA approved a once-monthly schizophrenia injection.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.